(Q37520986)

20 August 2017

1 reference

title

Risk of fractures with glitazones: a critical review of the evidence to date (English)

1 reference

20 August 2017

1 reference

Michael Bodmer

1

1 reference

20 August 2017

Christian Meier

series ordinal

2

1 reference

20 August 2017

Marius E Kraenzlin

series ordinal

3

1 reference

20 August 2017

Christoph R Meier

series ordinal

4

1 reference

20 August 2017

language of work or name

1 reference

1 January 2009

1 reference

20 August 2017

1 reference

20 August 2017

32

1 reference

20 August 2017

7

1 reference

20 August 2017

539-547

1 reference

https://scigraph.springernature.com/pub.10.2165/00002018-200932070-00001

20 August 2017

0 references

cites work

PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00002018-200932070-00001

Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00002018-200932070-00001

Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women

21 January 2018

1 reference

12 December 2020

Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARgamma agonist BRL49653 (rosiglitazone).

1 reference

12 December 2020

Older women with diabetes have a higher risk of falls: a prospective study

1 reference

12 December 2020

Age- and Gender-Specific Rate of Fractures in Australia: A Population-Based Study

1 reference

12 December 2020

Distinct effects of PPARgamma insufficiency on bone marrow cells, osteoblasts, and osteoclastic cells

1 reference

12 December 2020

Mechanisms of disease: is osteoporosis the obesity of bone?

1 reference

12 December 2020

Thiazolidinediones in type 2 diabetes: a cardiology perspective

1 reference

12 December 2020

Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men

1 reference

12 December 2020

Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial

1 reference

12 December 2020

Third-line agent selection for patients with type 2 diabetes mellitus uncontrolled with sulfonylureas and metformin

1 reference

12 December 2020

PPAR-gamma regulates osteoclastogenesis in mice

1 reference

12 December 2020

Use of thiazolidinediones and fracture risk

1 reference

12 December 2020

Osteopenia and metatarsal fractures in diabetic neuropathy

1 reference

12 December 2020

Fracture risk is a class effect of glitazones

1 reference

12 December 2020

Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation

1 reference

12 December 2020

1 reference

12 December 2020

The epidemiology of polycystic ovary syndrome. Prevalence and associated disease risks

1 reference

12 December 2020

Winners and losers at the rosiglitazone gamble A meta-analytical approach at the definition of the cardiovascular risk profile of rosiglitazone

1 reference

12 December 2020

Limb fractures in a defined population. I. Frequency and distribution

1 reference

12 December 2020

Treatment of type 2 diabetes with combined therapy: what are the pros and cons?

1 reference

12 December 2020

Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive

1 reference

12 December 2020

Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the health, aging, and body composition study

1 reference

12 December 2020

Skeletal consequences of thiazolidinedione therapy

1 reference

12 December 2020

Effects of low-dose prednisone on bone metabolism

1 reference

12 December 2020

Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT).

1 reference

12 December 2020

Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk

1 reference

12 December 2020

Pioglitazone administration decreases cardiovascular disease risk factors in insulin-resistant smokers

1 reference

12 December 2020

The controversial effects of thiazolidinediones on cardiovascular morbidity and mortality

1 reference

12 December 2020

Diabetes mellitus and the risk of non-vertebral fractures: the Tromsø study

1 reference

12 December 2020

Thiazolidinediones for treatment of polycystic ovary syndrome

1 reference

12 December 2020

The safety of rosiglitazone in the treatment of Type 2 diabetes

1 reference

12 December 2020

Effects of pioglitazone on lipid and lipoprotein metabolism

1 reference

12 December 2020

Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone

1 reference

12 December 2020

Activation of peroxisome proliferator-activated receptor-gamma pathway inhibits osteoclast differentiation

1 reference

12 December 2020

Diabetes and bone loss at the hip in older black and white adults

1 reference

12 December 2020

Potential benefits of early addition of rosiglitazone in combination with glimepiride in the treatment of type 2 diabetes

1 reference

12 December 2020

Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial

1 reference

12 December 2020

Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis

1 reference

12 December 2020

Regulation of bone mass in mice by the lipoxygenase gene Alox15

1 reference

12 December 2020

Older women with diabetes have an increased risk of fracture: a prospective study

1 reference

12 December 2020

The PROactive study: some answers, many questions

1 reference

12 December 2020

Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients

1 reference

12 December 2020

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial

1 reference

12 December 2020

Diabetes drugs tied to fractures in women

1 reference

12 December 2020

The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial

1 reference

12 December 2020

Risk of Fracture in Women with Type 2 Diabetes: the Women’s Health Initiative Observational Study

1 reference

12 December 2020

Thiazolidinediones inhibit osteoclast-like cell formation and bone resorption in vitro

1 reference

12 December 2020

Peroxisome proliferator-activated receptors (PPARs) in the control of bone metabolism.

1 reference

12 December 2020

Rosiglitazone decreases serum bone-specific alkaline phosphatase activity in postmenopausal diabetic women

1 reference

12 December 2020

Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials

1 reference

12 December 2020

Thiazolidinedione use and bone loss in older diabetic adults

1 reference

12 December 2020

Short-term treatment with troglitazone decreases bone turnover in patients with type 2 diabetes mellitus.

1 reference

12 December 2020

Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells

1 reference

12 December 2020

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

1 reference

12 December 2020

The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients

1 reference

12 December 2020

PPAR agonists modulate human osteoclast formation and activity in vitro

1 reference

12 December 2020

Brittle bones in spontaneously diabetic female rats cannot be predicted by bone mineral measurements: studies in diabetic and ovariectomized rats.

1 reference

12 December 2020

Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

12 December 2020

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

1 reference

12 December 2020

Diabetes and Incidence of Functional Disability in Older Women

1 reference

12 December 2020

Thiazolidinedione-induced skeletal fragility--mechanisms and implications

1 reference

12 December 2020

Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial

1 reference

12 December 2020

10.2165/00002018-200932070-00001

Identifiers

DOI

1 reference

Dimensions Publication ID

20 August 2017

0 references

1 reference